You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

112 Results
Guidelines and Advice
Status: Current
ID: GL-C50-13
Feb 2014
Guidelines and Advice
Status: Current
ID: GL-C50-11
Jan 2014
Guidelines and Advice
Status: Current
ID: GL-C50-14
Mar 2014
Statistical Reports
Jan 2014
Statistical Reports
Apr 2014
Guidelines and Advice
Status: Current
Jun 2014
Guidelines and Advice
Jul 2014
Guidelines and Advice
Status: Current
ID: GL-C50-15
Jun 2014
Drug
Other Name(s): Trelstar® (Allergan Pharma)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2014
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    fruquintinib - For the treatment of metastatic colorectal cancer according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
fruquintinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Drug
Other Name(s): Zoladex® , Zoladex® LA
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2026

Pages